Abstract
AimThis research focused on the results of the cross-validation program related with the performance of a Cuban novel low-cost real-time quantitative polymerase chain reaction (qPCR) assay for hepatitis B virus (HBV) quantification developed by the Therapeutic Vaccine against Hepatitis B Department, Vaccines Division, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.Materials and methodsDilution series with the plasmid standard at concentrations of 900,000 to 0.09 copies/reaction (c/r) were made for each PCR instrument. The mean cycles threshold (Ct) values and PCR efficiency were compared among the cyclers. Hepatitis B virus-positive serum samples were used for the calculation of reproducibility of the HBV assay. Biotecon Diagnostics (BCD) also ordered the oligo sequences from a second supplier and compared the PCR performance to those provided from the CIGB.ResultsAll PCR cyclers were able to detect concentrations up to 0.09 c/r. However, below the concentration of 9 c/r, the variation of results increased within and between the cyclers. The PCR efficiency showed satisfying results. The overall coefficient of variation (CV) cycler values were 1.29 and 0.91% for M6 and M19 respectively. No significance was observed between the different primer suppliers.ConclusionThe HBV assay was performed with a good concordance between the five real-time instruments from different suppliers. The HBV assay was also performed with a high reproducibility for samples with a high and a low viral load. The HBV assay is robust against different primer suppliers.How to cite this article: Aguiar J, Silva JA, García G, Guillén G, Aguilar JC. Cross-validation Studies of a Novel Low-cost Hepatitis B Virus Quantitative Polymerase Chain Reaction System. Euroasian J Hepato-Gastroenterol 2018;8(1):38-41.
Highlights
The hepatitis B virus (HBV) is the most common worldwide cause of viral hepatitis in humans
The HBV assay was performed with a good concordance between the five real-time instruments from different suppliers
The HBV assay was performed with a high reproducibility for samples with a high and a low viral load
Summary
Over 400 million persons have become chronic carriers of the virus, and over 20% of them will develop hepatocellular carcinoma.[1] Traditionally, the quantitative determination of the HBV level in the blood (viral load) is a basic variable in the follow-up and classification of the condition in patients with chronic hepatitis B. We described the characteristics and validation experiments of a cheap and simple qPCR method[8] that uses an unspecific and not very expensive commercial amplification kit (the Quantitect SYBR Green PCR kit, Qiagen, Germany) This was combined with the standards (based on a plasmid carrying the full-length HBV genome) and specific primers for the S gene, both produced at the CIGB, Havana, Cuba. The new combined kit was used to measure the concentration
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
